RCUS

Arcus Biosciences Inc

Add to Watchlist

Advanced Chart

8.540

-0.130(-1.500%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

8.840

Open

8.610

VWAP

8.56

Vol

849.07K

Mkt Cap

904.26M

Low

8.375

Amount

7.27M

EV/EBITDA(TTM)

Total Shares

90.95M

-30.98M

EV/OCF(TTM)

P/S(TTM)

5.73

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

32.86M

-15.75%

-1.165

+14.25%

32.48M

-32.33%

-1.182

+18.23%

29.61M

-17.76%

-1.210

+17.51%

Estimates Revision

The market is revising Downward the revenue expectations for Arcus Biosciences, Inc. (RCUS) for FY2025, with the revenue forecasts being adjusted by -43.31% over the past three months. During the same period, the stock price has changed by -22.08%.

Revenue Estimates for FY2025

Revise Downward

-43.31%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+30.14%

In Past 3 Month

Stock Price

Go Down

-22.08%

In Past 3 Month

10 Analyst Rating

241.10% Upside

Wall Street analysts forecast RCUS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RCUS is 29.13 USD with a low forecast of 14.00 USD and a high forecast of 46.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

1 Hold

0 Sell

Strong Buy

241.10% Upside

Current: 8.540

Low

14.00

Averages

29.13

High

46.00

241.10% Upside

Current: 8.540

Low

14.00

Averages

29.13

High

46.00

Morgan Stanley

Terence Flynn

Buy

Maintains

$24 → $22

2025-05-09

Reason

Morgan Stanley

Terence Flynn

Price Target

$24 → $22

2025-05-09

Maintains

Buy

Reason

Goldman Sachs

Salveen Richter

Hold

Maintains

$15 → $13

2025-05-08

Reason

Goldman Sachs

Salveen Richter

Price Target

$15 → $13

2025-05-08

Maintains

Hold

Reason

Barclays

Peter Lawson

Buy

Maintains

$29 → $14

2025-04-23

Reason

Barclays

Peter Lawson

Price Target

$29 → $14

2025-04-23

Maintains

Buy

Reason

HC Wainwright & Co.

Emily Bodnar

Hold

Strong Buy

Upgrades

$24

2025-02-26

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

$24

2025-02-26

Upgrades

Hold

Strong Buy

Reason

B of A Securities

Jason Zemansky

Hold

Maintains

$22 → $17

2025-02-19

Reason

B of A Securities

Jason Zemansky

Price Target

$22 → $17

2025-02-19

Maintains

Hold

Reason

Morgan Stanley

Terence Flynn

Buy

Maintains

$36 → $25

2025-02-18

Reason

Morgan Stanley

Terence Flynn

Price Target

$36 → $25

2025-02-18

Maintains

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Arcus Biosciences Inc (RCUS.N) is -1.91, compared to its 5-year average forward P/E of -5.58. For a more detailed relative valuation and DCF analysis to assess Arcus Biosciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.58

Current PE

-1.91

Overvalued PE

0.77

Undervalued PE

-11.93

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.59

Current EV/EBITDA

-0.02

Overvalued EV/EBITDA

0.27

Undervalued EV/EBITDA

-9.44

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

16.48

Current PS

6.20

Overvalued PS

27.06

Undervalued PS

5.89

Financials

Annual

Quarterly

FY2025Q1

YoY :

-80.69%

28.00M

Total Revenue

FY2025Q1

YoY :

-3150.00%

-122.00M

Operating Profit

FY2025Q1

YoY :

+2700.00%

-112.00M

Net Income after Tax

FY2025Q1

YoY :

+2180.00%

-1.14

EPS - Diluted

FY2025Q1

YoY :

+2116.67%

-133.00M

Free Cash Flow

FY2025Q1

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2025Q1

YoY :

+14392.75%

-400.00

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

20.3K

USD

Bought

0-3

0.0

USD

Months

3-6

15.4M

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

87.5K

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

1.4M

Volume

Months

3-6

2.4M

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

20.3K

USD

Bought

0-3

0.0

USD

Months

3-6

15.4M

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

RCUS News & Events

Events Timeline

2025-05-06 (ET)

2025-05-06

16:27:08

Arcus Biosciences reports Q1 EPS ($1.14), consensus ($1.01)

2025-02-25 (ET)

2025-02-25

16:29:02

Arcus Biosciences reports Q4 EPS ($1.03), consensus ($1.20)

2025-02-18 (ET)

2025-02-18

12:01:26

Arcus Biosciences falls -14.8%

News

6.0

05-08Benzinga

Goldman Sachs Maintains Neutral on Arcus Biosciences, Lowers Price Target to $13

9.5

05-06Benzinga

Ichor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

2.0

05-06Benzinga

Why ThredUp Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket

People Also Watch

NAPCO Security Technologies Inc

Alexander & Baldwin Inc (Hawaii)

Apartment Investment and Management Co

FAQ

What is Arcus Biosciences Inc (RCUS) stock price today?

The current price of RCUS is 8.54 USD — it has decreased -1.5 % in the last trading day.

RCUS

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

RCUS News & Events

Events Timeline

News

People Also Watch

FAQ

What is Arcus Biosciences Inc (RCUS) stock price today?

What is Arcus Biosciences Inc (RCUS)'s business?

What is the price predicton of RCUS Stock?

What is Arcus Biosciences Inc (RCUS)'s revenue for the last quarter?

What is Arcus Biosciences Inc (RCUS)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Arcus Biosciences Inc (RCUS)'s fundamentals?

How many employees does Arcus Biosciences Inc (RCUS). have?

What is Arcus Biosciences Inc (RCUS) market cap?